Biofrontera Inc Asset Resilience Ratio
Biofrontera Inc asset resilience ratio. Biofrontera Inc (BFRI) has an Asset Resilience Ratio of 0.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biofrontera Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biofrontera Inc (2021–2025)
Asset resilience ratio of Biofrontera Inc from 2021 to 2025. This chart shows how Biofrontera Inc's Asset Resilience Ratio has changed over time. Read Biofrontera Inc (BFRI) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biofrontera Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Biofrontera Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.00K | 0.03% |
| Total Liquid Assets | $8.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Biofrontera Inc maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biofrontera Inc Industry Peers by Asset Resilience Ratio
Compare Biofrontera Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Biofrontera Inc Asset Resilience Ratio by Year (2021–2025)
Biofrontera Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Biofrontera Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | $9.00K | $28.56 Million | 0.00pp |
| 2024-12-31 | 0.03% | $7.00K | $22.10 Million | -0.25pp |
| 2023-12-31 | 0.28% | $78.00K | $27.93 Million | -20.45pp |
| 2022-12-31 | 20.73% | $10.55 Million | $50.88 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $53.22 Million | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more